Renazorb News and Research

RSS
Spectrum Pharmaceuticals reveals positive RenaZorb Phase 1 clinical trial results

Spectrum Pharmaceuticals reveals positive RenaZorb Phase 1 clinical trial results

Spectrum initiates enrollment in RenaZorb Phase 1 trial in healthy volunteers

Spectrum initiates enrollment in RenaZorb Phase 1 trial in healthy volunteers

Spectrum seeks FDA IND approval for SPI-014 to treat hyperphosphatemia

Spectrum seeks FDA IND approval for SPI-014 to treat hyperphosphatemia

Spectrum Pharmaceuticals receives $977,900 grant under QTDP program

Spectrum Pharmaceuticals receives $977,900 grant under QTDP program

Spectrum Pharmaceuticals acquires rights and IP for Renazorb

Spectrum Pharmaceuticals acquires rights and IP for Renazorb